Merck’s ZIOPTAN for reducing elevated IOP receives FDA approval
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved ZIOPTANTM (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution.